66 -12 (74) 2024 - Ashurov F.Z. - COPD AS A COMORBID CONDITION IN COVID-19

COPD AS A COMORBID CONDITION IN COVID-19

Ashurov F.Z. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

Objective: To present current data on the problem of the comorbidity of chronic obstructive pulmonary disease (COPD) and the new coronavirus infection (COVID-19), according to the literature. The review summarizes and systematizes modern ideas about the association of COPD and COVID-19 and highlights the most important aspects of this problem - epidemiological, pathogenetic, clinical. The results of meta-analyses on the impact of COPD on the course of COVID-19 infection are presented. The need for further clinical studies on the problem of the comorbidity of COPD and COVID-19 has been shown, which will allow a detailed study of the mechanisms of mutual aggravation of the associated pathology, to find out the effect of SARS-CoV-2 on the respiratory system and the course of COPD, taking into account the phenotype of the disease, to determine effective treatment methods and to improve the prognosis of patients with COPD who have undergone the new coronavirus infection -COVID-19

Key words: comorbid, COVID-19, chronic obstructive pulmonary disease

First page

342

Last page

345

For citation:Ashurov F.Z. - COPD AS A COMORBID CONDITION IN COVID-19//New Day in Medicine 12(74)2024 342-345 https://https://newdayworldmedicine.com/en/new_day_medicine/12-74-2024

List of References

  1. World Health Organization. https://covid19.who.int/table.
  2. Grinevich VB, Gubonina IV, Doshchitsin VL, et al. Features of the management of comorbid patients during the pandemic of a new coronavirus infection (COVID-19). National Consensus 2020 // Cardiovascular Therapy and Prevention. 2020;19(4):2630.
  3. Pavlenko V.I., Kulik E.G., Naryshkina S.V., Kolosov V.P. Modern anti-inflammatory therapy of chronic obstructive pulmonary disease of varying risk of exacerbations. Amur State Medical Academy of the Ministry of Health of the Russian Federation. Blagoveshchensk. 2020. 127 p.
  4. Bhutani M, Hernandez P, Bourbeau J, et al. Addressing therapeutic questions to help Canadian health care professionals optimize COPD management for their patients during the COVID-19 pandemic // Canadian Journal of Respiratory Critical Care and Sleep Medicine. 2020. In press.
  5. Chalmers JD, Laska IF, Franssen FME, et al. Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. Eur Respir J. 2020. 55(6). 2000351. doi: 10.1183/13993003.00351- 2020.
  6. COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD) NICE guideline. www.nice.org.uk/guidance/ng168. Link active as of 02/15/21.
  7. Daccord C., Touilloux B., Von Garnier C. Asthma and COPD management during the COVID-19 pandemic // Rev. Med. Suisse. 2020. 16 (692). P.933–938.
  8. Emami A., Javanmardi F., Pirbonyeh N., Akbari A. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis // Arch Acad Emerg Med. 2020. 24; 8(1):e35.
  9. Fang X., Li S., Yu H., et al. Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis // Aging (Albany NY). 2020. 12(13). P.12493-12503. doi: 10.18632/aging.103579.
  10. Geerdink JX, Simons SO, Pike R, et al. Differences in systemic adaptive immunity contribute to the 'frequent exacerbator' COPD phenotype // Respir Res. 2016. 17. P.140. doi: 10.1186/s12931-016-0456-y.

    file

    download